 Home > Medical News > Latest Medical News > Takeda's new oral small molecule drug mobocertinib capsule is included in priority review in China

Takeda's new oral small molecule drug mobocertinib capsule is included in priority review in China

 Last Update: 2021-08-15
 Source: Internet
 Author: User

Tags

drug compendia

what drug interaction

interferon drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 12, the CDE official website announced that Takeda's new oral small molecule drug mobocertinib capsule has been officially accepted by the State Food and Drug Administration

According to the entry priority review record, the indications for this application for marketing are: treatment of locally advanced or metastatic non-small cell lung cancer ( NSCLC) adult patients

EGFR mutations are common gene mutations in patients with non-small cell lung cancer, accounting for about 10% to 15%.

Mobocertinib is a next-generation small molecule tyrosine kinase inhibitor (TKI), specifically designed to selectively inhibit epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) exon 20 mutations

Data from a phase I/II clinical trial (NCT0271611) proved the efficacy and safety of mobocertinib

The safety of Mobocertinib is controllable.

According to the PharmaGo database of Medicine Rubik's Cube, among the drugs under development in China that target EGFR Exon20, in addition to Takeda's mobocertinib, which has been declared for marketing, Dizhe Medicine DZD9008 is in the phase II clinical stage

Original title: The first insertion mutation therapy for EGFR/HER2 Exon20 was declared for marketing in China and included in priority review

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.